Karyopharm shareholders approve 6M share increase in equity plan, 5M in ESPP, and option exchange

Karyopharm Therapeutics Inc.

Stockholders approved Class II directors: Deepika R. Pakianathan, Richard Paulson, Chen Schor (all three-year terms).
Amendment to 2022 Equity Plan approved: adds 6,000,000 shares for issuance.
ESPP Amendment approved: adds 5,000,000 shares for issuance.
Stockholders approved a one-time stock option exchange program for non-executive officer employees.
Ratified Ernst & Young as independent auditor for FY2024 (87.7M for, 2.5M against).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.